Sanofi has licensed a potential treatment for Crohn's disease from India's Glenmark Pharmaceuticals.
The drug in question is GBR500, a novel monoclonal antibody to treat Crohn’s and other chronic autoimmune disorders. It is a first-in-class antagonist of the VLA-2 (alpha2-beta1) integrin and has completed a Phase I study in the USA; the treatment has been well tolerated with a good pharmacokinetic profile.
Under the terms of the agreement, Glenmark will receive an upfront fee of U$50 million, of which $25 million will be paid upon closing of the transaction. The remainder is contingent upon Sanofi’s "positive assessment of certain data" to be provided by the Mumbai-headquartered firm.
In addition, Glenmark could receive potential success-based development, regulatory and commercial milestone payments worth over $600 million, plus double-digit royalties. Sanofi is getting exclusive marketing rights in North America, Europe, Japan, Mexico, Argentina, Chile and Uruguay, and co-marketing or co-promotion rights in Brazil, Russia, Australia and New Zealand. Glenmark will retain rights in India and the rest of the world.
Sanofi R&D chief Elias Zerhouni said “there continues to be a strong medical need for safer and more efficacious products for the treatment of inflammatory diseases”. He added that GBR500 "may address a significant gap" in treating such conditions.
Glenn Saldanha, Glenmark's chief executive, said the deal validates his company's "world-class innovative R&D capabilities in the drug discovery area" The two firms are already working together on investigational treatments for pain, after a deal worth up to $325 million was signed a year ago.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.